|
Active substance |
Avelumab |
|
Holder |
Merck nv/sa |
|
Status |
Closed |
|
Indication |
Treatment of adult patients with metastatic Merkel cell carcinoma whose disease has progressed after receiving at least one prior chemotherapy or who are ineligible for chemotherapy |
|
Public documents |
|
|
Last update |
01/08/2018 |
Bavencio
Last updated on 23/04/2024